A review in The Lancet Neurology (September 2026) addresses a common dilemma. Conduction abnormalities and bradycardia are frequent in dementia with Lewy bodies, probably through autonomic involvement, and cholinesterase inhibitors are often withheld for fear of worsening them.
The authors summarise randomised trial and meta-analysis evidence supporting a favourable cardiac safety profile for cholinesterase inhibitors in Lewy body dementia, and emerging evidence that patients with cardiac conduction abnormalities can be treated without an increase in major cardiovascular events. They propose an approach built on cardiac screening and monitoring rather than avoidance.
This is a narrative review with expert recommendations, not new trial data. But cholinesterase inhibitors are the most effective treatment for cognitive and neuropsychiatric symptoms in this disease, so withholding them has a real cost.
- Take an ECG before starting a cholinesterase inhibitor in Lewy body dementia
- Do not withhold treatment solely for mild bradycardia or first-degree block — discuss with cardiology where uncertain
- Repeat the ECG and ask about syncope and falls after starting and after each dose increase
- Refer higher-grade block or symptomatic bradycardia for cardiology assessment, including whether pacing would allow treatment
Why it matters
Patients with the most to gain from cholinesterase inhibitors are often denied them on cardiac grounds the evidence does not strongly support.
Don't overread it
This is a narrative review; the evidence in patients with established conduction disease is still limited.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free